Clinical Study

Pre0905- Randomized Trial Of Gilteritinib Vs Midostaurin In Flt3 Mutated Acute Myeloid Leukemia (Aml)

Posted Date: Dec 19, 2020

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AM. Patients will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation.


To Be Eligible: Must Have Previously Untreated Flt3 Mutated Non M3 Aml , Adequate Organ Function, Ecog 0-3, No Cns Leukemia, No Hypomethylating Agent Within 21 Days, No Other Malignancy, No Uncontrolled Cardiac Issues Or Infection, No Hypersensitivity To Study Drugs Or Components


Leukemia, Aml, Acute Myeloid Leukemia

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.